|
Adverse cardiovascular effects of remdesivir in COVID-19 patients
|
Fatemah Abedipour   , Asma Rashki |
|
|
|
Abstract: (326 Views) |
Introduction: There have been reports of serious side effects of remdesivir, including cardiovascular complications. Since remdesivir is one of the recommended drugs to treat covid-19; therefore, the present study aimed at determining the adverse cardiovascular effects of remdesivir and the factors contributing to them in COVID-19 patients.
Methods and Materials: This study is a case-control design consisting of two groups. It involved 200 patients hospitalized with COVID-19 and treated with Remdesivir at Ali Bin Abitalib and Bu Ali public hospitals in Zahedan city in 1401. To evaluate both study groups, we reviewed the patient's medical records and completed an information form. This allowed us to gather important information, such as the patient's age, sex, height, and weight, as well as whether they were hospitalized in the ward or ICU if they had any underlying diseases, and if they were taking any other medications. Additionally, we assessed their levels of serum electrolytes (potassium and magnesium), liver enzymes, and serum creatinine. Then, the relationship between the above factors and the incidence of adverse cardiovascular effects of remdesivir was measured. Data analysis was done using descriptive statistics and independent t-tests, chi-square, Fisher's exact, and Mann-Whitney tests. A p-value of less than 0.05 was considered significant.
Results: Many of the research subjects experienced sinus bradycardia complications and, according to the chi-square test, the distribution of complications in men was significantly higher than in women (P=0.001). Furthermore, the independent t-test showed that the mean age in the group with complications was significantly higher than in the group without complications (P=0.013). On the other hand, Fisher's exact test demonstrated a significant relationship between smoking and cardiovascular complications (P=0.05). According to the Mann-Whitney test, a significant difference was found in the mean changes of bilirubin (P=0.02) and ALKP (P=0.01) before and after treatment in both groups.
Conclusion: Our findings indicated that most of the patients with COVID-19 suffered from sinus bradycardia, and the complications were more frequent in men than in women. The mean changes of bilirubin and ALKP before and after treatment were significantly different in both groups. Thus, prescribing remdesivir for COVID-19 patients requires caution and continuous ECG monitoring. Further studies with higher power and quality are necessary.
|
|
| Keywords: Remdesivir, Cardiovascular system, Sid effects, Covid-19 |
|
|
Full-Text [PDF 249 kb]
(61 Downloads)
|
Type of Study: Research |
Subject:
General
Received: 2024/01/10 | Accepted: 2023/08/23 | Published: 2023/08/23
|
|
|
|
|
|
